Episode Details
Back to Episodes
Cencora's Q1 Earnings: Revenue Misses, But Profit Stable
Description
Cencoras Q1 earnings missed Wall Streets expectations due to faster-than-expected shifts to biosimilar drugs and client losses. However, the company raised its full-year adjusted earnings per share forecast and maintained steady operating margins. Analysts questioned the impact of biosimilar conversions and client losses on operating profit, to which management explained that these issues primarily affect revenue, not profitability. The focus now shifts to stabilizing biosimilar conversions and international logistics growth, as investors await a potential buying opportunity amidst the stocks post-earnings dip.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/bf03ba3a63629302